China Meheco(SH:600056)2014-04-28 16:00Financial Performance - Operating revenue for the quarter was CNY 3.97 billion, an increase of 11.59% from the same period last year[10] - Net profit attributable to shareholders was CNY 132.95 million, reflecting a 2.62% increase year-over-year[10] - Basic earnings per share decreased by 0.91% to CNY 0.2807 compared to the previous quarter[10] - Total operating revenue for the current period reached CNY 3,965,734,576.59, an increase of 11.6% compared to CNY 3,553,984,545.62 in the previous period[39] - Net profit attributable to the parent company was CNY 132,946,118.06, a slight increase from CNY 129,556,561.30, representing a growth of 2.0%[40] - The total comprehensive income for the current period was CNY 116,020,210.58, compared to CNY 139,790,742.29 in the previous period, reflecting a decrease of 17.0%[40] Assets and Liabilities - Total assets increased by 12.77% to CNY 14.42 billion compared to the end of the previous year[10] - Total assets increased to CNY 6,054,695,952.95 from CNY 5,142,451,244.98, marking a growth of 17.7%[36] - Total liabilities decreased to CNY 2,179,773,230.53 from CNY 2,294,499,603.67, a reduction of 5.0%[37] - Current liabilities totaled CNY 7,606,100,246.52, compared to CNY 7,034,451,924.21 at the beginning of the year, representing an increase of approximately 8.1%[33] Shareholder Information - The total number of shareholders as of the report date was 38,475[13] - The largest shareholder, China General Technology (Group) Holding, owns 43.56% of the shares[13] - Shareholders' equity rose to CNY 3,874,922,722.42, up from CNY 2,847,951,641.31, indicating a growth of 36.0%[37] Cash Flow - The company reported a net cash flow from operating activities of CNY -372.63 million, an improvement from CNY -643.90 million in the previous year[10] - Cash and cash equivalents increased by 821.79 million yuan, a growth of 41.90% compared to the beginning of the period, mainly due to the funds raised from the non-public offering of shares in the first quarter[14] - Cash received from investment increased by 960 million yuan, mainly due to the funds raised from the non-public offering of shares in the first quarter[14] - Total cash inflow from operating activities is ¥3,795,290,260.93, up 12.9% from ¥3,360,921,848.88 in the previous period[43] - Cash outflow from operating activities is ¥4,167,920,254.50, an increase of 4.1% compared to ¥4,004,820,184.94 in the previous period[44] - The ending cash and cash equivalents balance is ¥2,249,955,752.64, up from ¥1,512,115,892.36 in the previous period[46] Government and Regulatory Matters - The company received government subsidies amounting to CNY 1.63 million related to its core business operations[11] - The company has committed to providing guarantees for the performance of contracts with the Venezuelan Ministry of Health, with no requests for guarantees made as of the report date[26] - China National Pharmaceutical Group plans to inject equity of General E-commerce into China Medicine within four years post-restructuring, subject to legal regulations[20] Corporate Actions and Commitments - China Medicine plans to merge with Henan Tianfang Pharmaceutical through a share exchange and non-public issuance of shares[24] - Tianfang Group has committed to transferring 66.67% equity of Heilongjiang Tianfang Pharmaceutical to a non-related third party to eliminate competition with China Medicine[21] - The commitment to maintain the independence of China Medicine from its controlling shareholder, China General Technology Group, remains in effect[23] - China General Technology Group guarantees that no funds will be occupied from China Medicine and its subsidiaries[23] - The financial company under China General Technology Group will continue to provide financial services to related companies, ensuring the safety of their funds[25]